Encellin
3EmployeesUS Form 5500 (plan participants) · Dec 2025 · 0% in a year
Lately:3 news stories in 90 daysFollow changes →
Facts
as of Nov 17, 2026Empowering living medicines.. Encellin is focused on advancing next generation therapies, starting with endocrine disorders.
- Legal name
- Encellin, Inc.
- Headquarters
- San Francisco, United States
- Founded
- 2015
- Employees
- 3US Form 5500 (plan participants) · Dec 2025 · 0% in a year
- Register numbers
- NAME encellin inc
- Official records
- SEC CIK 1782948
- Website
- encellin.com
These are the key facts about Encellin on Alion as of Nov 17, 2026. Encellin is headquartered in San Francisco, United States. It was founded in 2015. It has raised $17.9M in 3 funding rounds. The latest round is Venture - Series Unknown of $9.9M, announced in 2023.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Legal entity active
Encellin, Inc.
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Footprint
Hiring in 1 city in 1 country.
1Cities
1Countries
| Site | Type | Open roles | Hires most for | Engineering |
|---|---|---|---|---|
| San Francisco United States | Headquarters | 0 |
Source: office addresses in postings and company registers
Financials
Funding rounds, investors and revenue on record.
$17.9MTotal raised
Venture - Series UnknownLatest round
3Rounds and grants
Money by yearUSD, rounds and grants
Largest rounds and grants
Sources: funding announcements, grant and company registers
Milestones
Sep 21
Sep 20, 2023
Raised a round Venture round $9.9M · SEC Form D
Aug 5, 2021
Raised a round Seed $5.9M · led by Khosla Ventures · businesswire
2015
Founded
Each milestone is dated by its source: registers, filings, the press
Newsroom
Sep 222026
News · YahooFinance
Encellin Partners with Breakthrough T1D to Advance Immune-Protected Cell Therapy for Type 1 Diabetes
SAN FRANCISCO & NEW YORK & MONTREAL, September 22, 2026--Encellin, Inc., a clinical-stage biotechnology company developing Encapsulated Cell Replacement Therapy (ENCRT), today an…
Sep 222026
Jan 62026
News · YahooFinance
SAN FRANCISCO, January 06, 2026--Encellin, a biotechnology company pioneering Encapsulated Cell Replacement Therapy (ENCRT), today announced interim clinical results from its ong…
Jan 62026
Press release · businesswire.com
On January 6th, 2026, Encellin reported positive interim results of its Phase 1 clinical trial of encapsulated islets in people with type 1 diabetes (T1D).
Dec 20, 20232023
News · Pulse 2.0
Encellin - a biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D) - recently announced the closing of a $9.9 million fina…
Dec 13, 20232023
Press release · businesswire
Encellin Closes $9.9M Financing Led by Khosla Ventures to Advance Cell Encapsulation Platform for Endocrine Disorders
Sources: the outlets named on each headline, each story once
